drugset / Trial / NCT00726752

A Study In Patients With Advanced Solid Tumor

NCT00726752

Phase 1 Completed 6 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses

Timeline

Start
2008-07
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg
Subject Axitinib Small molecule 7 mg
Subject Axitinib Small molecule 10 mg

Indications